Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Phase 2

Not yet recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Golidocitinib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2024-10-08

Last Posted Date: 2024-10-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06630091

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

First Posted Date: 2024-10-03

Last Posted Date: 2024-10-03

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 12

Registration Number: NCT06626256

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Ciltacabtagene Autoleucel
Radiation: Total body irradiation

First Posted Date: 2024-10-02

Last Posted Date: 2024-12-18

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 12

Registration Number: NCT06623630

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Phase 3

Not yet recruiting

Conditions: Graft-versus-host Disease (GVHD)

Interventions: Drug: Tacrolimus (Tac)
Drug: Methotrexate (MTX)
Drug: Cyclophosphamide
Drug: Ruxolitinib (Rux)
Drug: Mycophenolate mofetil (MMF)

First Posted Date: 2024-09-26

Last Posted Date: 2024-12-04

Lead Sponsor: Incyte Corporation

Target Recruit Count: 572

Registration Number: NCT06615050

The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy

Phase 2

Not yet recruiting

Conditions: Primary Membranous Nephropathy

Interventions: Drug: Prednisone
Drug: Telitacicept
Drug: Cyclophosphamide

First Posted Date: 2024-09-26

Last Posted Date: 2024-09-26

Lead Sponsor: Renmin Hospital of Wuhan University

Target Recruit Count: 172

Registration Number: NCT06614985

Locations: 🇨🇳
Renmin Hospital of Wuhan university, Wuhan, Hubei China, China

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3

Not yet recruiting

Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)

Interventions: Drug: BMS-986393
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Carfilzomib
Drug: Daratumumab
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2024-09-26

Last Posted Date: 2024-12-20

Lead Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Target Recruit Count: 440

Registration Number: NCT06615479

Locations: 🇦🇺
Local Institution - 0190, Liverpool, New South Wales, Australia
🇦🇺
Local Institution - 0191, Melbourne, Victoria, Australia
🇺🇸
Local Institution - 0071, Birmingham, Alabama, United States

and more 108 locations